Overall and per inhabitant costs per saved cardiovascular events according to randomised trials and drug costs (Apulia region, South-Eastern Italy)
| Endpoint | ARR | NNT | Cost per saved event per year, € (millions) | Cost per saved event per year per inhabitant, € | Saved events with €1 per inhabitant per year |
| ODYSSEY OUTCOMES | |||||
| All-cause death | 0.6 | 163 | 2.1 | 0.51 | 2.0 |
| MI | 1 | 100 | 1.3 | 0.31 | 3.2 |
| Stroke | 0.4 | 250 | 3.2 | 0.78 | 1.3 |
| MACE* | 1.9 | 53 | 0.7 | 0.16 | 6.1 |
| Death, MI, stroke | 1.6 | 64 | 0.8 | 0.20 | 5.0 |
| LDL baseline levels >100 mg/dL | |||||
| Death, MI, stroke | 3.4 | 29 | 0.4 | 0.09 | 10.9 |
| All-cause death | 1.7 | 60 | 0.8 | 0.19 | 5.3 |
| FOURIER | |||||
| MI | 1.9 | 53 | 0.5 | 0.13 | 7.9 |
| Stroke | 0.4 | 250 | 2.4 | 0.60 | 1.7 |
| MACE† | 2 | 50 | 0.5 | 0.12 | 8.3 |
| CV death, MI, stroke | 2 | 50 | 0.5 | 0.12 | 8.3 |
| Multivessel coronary disease | |||||
| MACE† | 3.6 | 28 | 0.3 | 0.07 | 15.0 |
| CV death, MI, stroke | 3.4 | 29 | 0.3 | 0.07 | 14.2 |
*Death from CV causes, non-fatal MI, unstable angina requiring hospitalisation, an ischaemia-driven coronary revascularisation procedure or non-fatal ischaemic stroke.
†Cardiovascular death, MI, stroke, hospitalisation for unstable angina, coronary revascularisation.
ARR, absolute risk reduction; CV, cardiovascular; FOURIER, Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; LDL, low-density lipoprotein; MACE, major adverse CV event; MI, myocardial infarction; NNT, number needed to treat; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab.